GlassScriptPhysician profile
Michael T Wingard
NPI 1932105020
$2,258.24
in general payments reported to CMS, 2019-2025
15 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $74.16 · 2021: $304 · 2022: $444 · 2023: $350 · 2024: $447 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941 · Entertainment: $16.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.65 |
| Entertainment | $16.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $498.56 | 2019-2023 | Misight Contact Lens, Biofinity Contact Lens |
| Alcon Vision LLC | $338.30 | 2022-2025 | Total30 |
| Biotissue Holdings INC. | $249.49 | 2019-2023 | |
| Allergan, INC. | $239.72 | 2021-2022 | |
| Lkc Technologies, INC. | $137.05 | 2024 | |
| Dompe US, INC. | $125.00 | 2024 | Oxervate |
| Rxsight INC | $103.41 | 2022 | |
| Genzyme Corporation | $100.00 | 2019 | |
| Abbott Laboratories | $98.66 | 2024 | Freestyle Libre 3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.74 | 2019 | |
| Amgen INC. | $86.32 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $85.91 | 2019 | |
| Shire North American Group INC | $65.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.76 | 2019 | |
| Optos, INC. | $16.36 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wingard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.